Vivos Inc., a publicly traded company incorporated in the United States, recently disclosed its financial results for the third quarter of 2026, revealing a continued trajectory of operating losses. The company, which trades on the OTC Bulletin Board, reported a net loss for the quarter that widened compared to the same period in 2025. This increase in losses was primarily attributed to high professional fees, payroll, and research and development expenditures. Additionally, the company faced a larger charge due to the issuance of shares and warrants, further impacting its financial performance.
Despite the negative cash flow from operating activities, Vivos Inc. managed to generate positive cash flow from financing activities. This was achieved through the sale of common stock and warrants, which helped offset investment outflows. As a result, the company’s balance sheet showed a modest increase in cash and liquidity. Both total assets and liabilities experienced modest growth, reflecting the company’s ongoing financial activities and strategic investments.
Vivos Inc. remains steadfast in its commitment to advancing its Y-90 based precision radionuclide therapy device, RadioGel™, and its veterinary counterpart, IsoPet®. The company is actively pursuing regulatory progress and clinical development for these innovative products. The focus on these therapeutic devices underscores Vivos Inc.’s dedication to addressing critical medical needs through cutting-edge technology.
As of May 14, 2026, Vivos Inc.’s close price stood at $0.066, with a 52-week high of $0.1547 recorded on July 21, 2025, and a 52-week low of $0.0425 on August 13, 2025. The company’s market capitalization is currently valued at $31,857,432 USD. Despite a negative price-to-earnings ratio of -9.44, Vivos Inc. continues to navigate its financial challenges while focusing on the potential of its core products to drive future growth and success.
